Metformin alternatives in prediabetes management
GLP-1 and SGLT2 use in prediabetes is challenging metformin's long-standing first-line position.
Metformin has been the default prediabetes pharmacotherapy for two decades. GLP-1 agonist and SGLT2 inhibitor use in prediabetes is now growing, particularly in patients with cardiovascular or weight-management considerations. Whether this becomes a routine first-line displacement or stays a comorbidity-driven niche depends on guideline body decisions over the next 18 months.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedWhat is type 1 diabetes?
- ExplainedWhat is ATTR cardiomyopathy?
TreatmentReal world evidencePatient journey
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.